SQLite Web: event_store.db

Update row 131065 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-18T03:05:05.644967+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:20fb7d3f18571532","evidence_event_ids":["evt_e263f3948a8c"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1599298/0001599298-26-000029.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1599298/0001599298-26-000029.txt","company":"Summit Therapeutics Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1599298/0001599298-26-000029.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_e560ac5326d6b81e","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1599298/0001599298-26-000029.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:42:43.648594+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"smmt-20260417","final_url":"https://www.sec.gov/Archives/edgar/data/1599298/0001599298-26-000029.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1599298/0001599298-26-000029.txt","source_event_id":"evt_e263f3948a8c","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"c1dcefdd6450be06","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-10","2026-04-15","2026-04-17","2026-04-18","2026-06-09","2026-06-10"],"entities":[{"asset_class":"equity","name":"Summit Therapeutics Inc.","relevance":"high","symbol":"SMMT","type":"issuer"},{"asset_class":"other","name":"PricewaterhouseCoopers LLP","relevance":"medium","symbol":"","type":"auditor"},{"asset_class":"other","name":"Robert W. Duggan","relevance":"medium","symbol":"","type":"executive"}],"event_type":"listing","information_gaps":["What specifically changed versus a prior known state is not provided in the signal text (no prior filing comparison content included).","The filing\u2019s amendment number is shown as \u201c(Amendment No.)\u201d but the amendment number value is not present in the provided text.","The proxy statement\u2019s detailed director nominees, executive compensation specifics, and the full rationale/terms of the stock incentive plan amendment are not included in the provided excerpt.","No explicit financial guidance or financial implications beyond the stock plan share increase are stated in the provided text."],"key_facts":["The filing is a definitive proxy statement on Schedule 14A (DEF 14A) for Summit Therapeutics Inc.","The annual meeting is scheduled for June 10, 2026 at 8:30 a.m. Eastern Daylight Time and will be conducted virtually via live webcast.","Stockholders will be asked to vote on: (1) elect nine directors, (2) ratify PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, (3) approve by non-binding advisory vote the compensation of named executive officers, and (4) amend the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase shares issuable under the Plan by 8,000,000 shares.","The record date for the annual meeting is April 15, 2026 (close of business).","The proxy statement is being mailed to stockholders on or about April 17, 2026.","Voting deadline stated: votes must be received by 11:59 p.m. Eastern Daylight Time on June 09, 2026 if voting via Internet/telephone/mail.","The notice indicates the filing fee is not required (No fee required checked)."],"numeric_claims":[{"label":"Annual meeting date","value":"2026-06-10"},{"label":"Annual meeting time (ET)","value":"8:30 a.m."},{"label":"Record date","value":"2026-04-15"},{"label":"Proxy mailing date (approx.)","value":"on or about 2026-04-17"},{"label":"Voting deadline (ET)","value":"2026-06-09 11:59 p.m."},{"label":"Number of directors to elect","value":"9"},{"label":"Shares increase under 2020 Stock Incentive Plan","value":"8,000,000"},{"label":"Fiscal year ending for auditor ratification","value":"2026-12-31"}],"primary_claim":"Summit Therapeutics Inc. filed a definitive proxy statement on Form DEF 14A for its 2026 annual meeting scheduled for June 10, 2026.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Summit Therapeutics Inc. filed a definitive proxy statement (DEF 14A) for its 2026 annual meeting of stockholders. The filing includes proposals to elect directors, ratify the independent auditor, approve advisory executive compensation, and amend its 2020 Stock Incentive Plan to increase shares by 8,000,000.","topics":["SEC filing","DEF 14A","proxy statement","annual meeting","board of directors","independent auditor","executive compensation (advisory)","stock incentive plan amendment","corporate governance"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Summit Therapeutics Inc. \u00b7 Filed 20260417","ticker":"SMMT","tickers":["SMMT"],"title":"SMMT filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1599298/0001599298-26-000029.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel